NDA 203565 · Am Regent
Injectafer
Ferric Carboxymaltose · Intravenous
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jul 25, 2013
Approved uses
5
Original approval plus efficacy supplements
Registered trials
194
58 Phase 3, 13 recruiting
FAERS reports
4,728
2,512 serious, 90 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SYMPTOMATIC HYPOPHOSPHATEMIA • FERRIC CARBOXYMALTOSE INJECTION can cause severe, prolonged hypophosphatemia associated with serious outcomes, including hospitalization, osteomalacia and fractures requiring clinical intervention [see Warnings and Precautions ( 5 . 1 )]. • Hypophosphatemia has occurred in patients with normal baseline phosphate levels and without apparent risk factors for hypophosphatemia [see Warnings and Precautions ( 5.1 )]. • Check serum phosphate levels prior to a repeat course of treatment in patients at risk for low serum phosphate and in any patient who receives a repeat course of therapy within three months [see Dosage and Administration ( 2.1 , 2.3) ] . Correct pre-existing hypophosphatemia prior to administering FERRIC CARBOXYMALTOSE INJECTION [see Warnings and Precautions ( 5.1 )] . • Advise patients receiving FERRIC CARBOXYMALTOSE INJECTION about the...
What it is approved for
From the label in effect Sep 2, 2026.
Ferric carboxymaltose injection is indicated for the treatment of: • Iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult patients who have non-dialysis dependent chronic kidney disease. • Iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. Ferric carboxymaltose injection is an iron replacement product indicated for the treatment of: • iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. ( 1 ) adult patients who have non-dialysis dependent chronic kidney disease. ( 1 ) • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. ( 1 )
Mechanism: Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 31, 2023 Supplement 20 · Efficacy LetterLabel
- Nov 19, 2021 Supplement 16 · Efficacy LabelLetter
- Apr 28, 2021 Supplement 14 · Efficacy LetterLabel
- Jan 26, 2018 Supplement 5 · Efficacy · priority review LabelLetter
- Jul 25, 2013 Original approval · Type 5 - New Formulation or New Manufacturer LabelSummary ReviewLetter
4 products under this application
- INJECTAFER · FERRIC CARBOXYMALTOSE 750MG IRON/15ML (50MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- INJECTAFER · FERRIC CARBOXYMALTOSE 100MG IRON/2ML (50MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- INJECTAFER · FERRIC CARBOXYMALTOSE 500MG IRON/10ML (50MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription
- INJECTAFER · FERRIC CARBOXYMALTOSE 1GM IRON/20ML (50MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ferric Carboxymaltose" as an intervention, any sponsor and status, largest first.
- Prevention of Iron Deficiency Anemia Post-deliveryPivotal-lookingCompleted
NICHD Global Network for Women's and Children's HealthResearch network
NCT05590260 · 4,857 participants · Start May 30, 2023 · Primary completion Mar 10, 2025
Drug: Ferric carboxymaltose (FCM) and folic acid tablets; Oral iron tablets and folic acid tablets · For: Postpartum Anemia
Sites: Dhaka, Bangladesh; Kinshasa, Democratic Republic of the Congo; Guatemala City, Guatemala · 8 sites in all
- Reducing Anemia in Pregnancy in India: the RAPIDIRON TrialPivotal-lookingCompleted
Thomas Jefferson UniversityAcademic, hospital or other
NCT05358509 · 4,368 participants · Start Mar 15, 2021 · Primary completion Dec 14, 2023
Drug: Ferric carboxymaltose; Iron isomaltoside and 1 more · For: Iron Deficiency Anemia; Infant, Low Birth Weight; Anemia of Pregnancy
Sites: Bagalkot, India; Belagavi, India; Rāichūr, India · 4 sites in all
- Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyPivotal-lookingCompleted
American Regent, Inc.Industry
NCT03037931 · 3,065 participants · Start Mar 15, 2017 · Primary completion Feb 2, 2023
Drug: Ferric Carboxymaltose; Placebo · For: Heart Failure; Iron-deficiency
Sites: Alexander City, Alabama; Auburn, Alabama; Mobile, Alabama · 345 sites in all
- Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum DepressionPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06833788 · 2,860 participants (planned) · Start Oct 22, 2025 · Primary completion Jun 22, 2028
Drug: Ferric carboxymaltose IV; TIMOFÉROL® · For: Postpartum Depression (PPD)
Sites: Paris, France
- Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal FunctionPivotal-lookingCompleted
American Regent, Inc.Industry
NCT00981045 · 2,561 participants · Start Aug 2009 · Primary completion Jul 2011
Drug: Ferric Carboxymaltose (FCM); Iron Sucrose (Venofer) · For: Iron Deficiency Anemia; Impaired Renal Function
Sites: Norristown, Pennsylvania
- Iron Supplementation in TAVI and SAVR Patients With Iron DeficiencyPivotal-lookingStatus unknown
Hospital de Santa Cruz, PortugalAcademic, hospital or other
NCT04786769 · 2,500 participants (planned) · Start Jan 2022 · Primary completion Jan 2025
Drug: Ferric carboxymaltose · For: Aortic Stenosis; Iron-deficiency
- Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum PatientsPivotal-lookingCompleted
American Regent, Inc.Industry
NCT00548860 · 2,018 participants · Start Oct 2007 · Primary completion Mar 2009
Drug: Ferric Carboxymaltose; Standard Medical Care (SMC) · For: Anemia
Sites: Norristown, Pennsylvania
- A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)Pivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT02694978 · 2,014 participants · Start Feb 29, 2016 · Primary completion Jan 16, 2017
Drug: Ferumoxytol; FCM · For: Iron Deficiency Anemia
Sites: Huntsville, Alabama; Tucson, Arizona; Anaheim, California · 127 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypophosphataemia871
- nausea553
- pain430
- dyspnoea399
- headache370
- product quality issue326
- dizziness310
- anxiety293
- urticaria288
- arthralgia280
- emotional distress259
- pruritus256
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 3 |
| 2014 | 45 |
| 2015 | 170 |
| 2016 | 205 |
| 2017 | 395 |
| 2018 | 473 |
| 2019 | 656 |
| 2020 | 525 |
| 2021 | 578 |
| 2022 | 628 |
| 2023 | 352 |
| 2024 | 252 |
| 2025 | 257 |
| 2026 | 189 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Injectafer (Ferric Carboxymaltose) · HCPCS J1439
2024 spending
$131M
Beneficiaries
73,218
147,578 claims
Per beneficiary
$1,793
2024 ASP limit $1.12 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $149,785,035 |
| 2021 | $161,942,228 |
| 2022 | $155,020,670 |
| 2023 | $147,399,186 |
| 2024 | $131,249,161 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P, Kirwan BA, Anker SD, et al. · Lancet 2020 · Multicenter Study, Randomized Controlled Trial
- Ferric Carboxymaltose (FCM)-Associated Hypophosphatemia (HPP): A Systematic Review.
Magagnoli J, Knopf K, Hrushesky WJ, et al. · Am J Hematol 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial.
Anker SD, Friede T, Butler J, et al. · JAMA 2025 · Clinical Trial, Phase IV, Multicenter Study
- Diagnosis and treatment of iron-deficiency anemia in gastrointestinal bleeding: A systematic review.
Cotter J, Baldaia C, Ferreira M, et al. · World J Gastroenterol 2020 · Meta-Analysis, Systematic Review
- A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.
Kennedy NA, Achebe MM, Biggar P, et al. · Int J Clin Pharm 2023 · Systematic Review, Meta-Analysis
- Single-dose intravenous iron vs oral iron for treatment of maternal iron deficiency anemia: a randomized clinical trial.
Derman RJ, Bellad MB, Somannavar MS, et al. · Am J Obstet Gynecol 2025 · Randomized Controlled Trial, Multicenter Study
Sponsor: Am Regent
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.